Gland Pharma's Q3 FY 2025-26 Quarterly Results
- 29 Jan 2026
Result Summary
- Gland Pharma Ltd reported a 11.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.9%.
- Its expenses for the quarter were up by 6.6% QoQ and 20.0% YoY.
- The net profit increased 42.4% QoQ and increased 27.7% YoY.
- The earnings per share (EPS) of Gland Pharma Ltd stood at 15.87 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 1758.54 | 1571.04 | 1442.55 | 11.9% | 21.9% |
Total Expenses | 1372.06 | 1287.12 | 1143.24 | 6.6% | 20.0% |
Profit Before Tax | 362.13 | 283.92 | 299.30 | 27.5% | 21.0% |
Tax | 100.65 | 100.23 | 94.61 | 0.4% | 6.4% |
Profit After Tax | 261.48 | 183.68 | 204.69 | 42.4% | 27.7% |
Earnings Per Share | 15.87 | 11.15 | 12.42 | 42.3% | 27.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Gland Pharma Ltd is a pharmaceutical company known for its focus on the development, manufacture, and marketing of complex injectables. The company operates primarily in the pharmaceutical industry, providing a range of injectable formulations to global markets. Gland Pharma is recognized for its robust product portfolio and emphasis on maintaining high-quality manufacturing standards. As of the data provided, there are no specific recent major developments mentioned for Gland Pharma Ltd. If there are any new initiatives or strategic changes, they are not available within the data provided.
Revenue
In Q3FY26, Gland Pharma Ltd reported a total income of ₹1758.54 crores. This represents an increase of 11.9% compared to the previous quarter (Q2FY26), where the total income was ₹1571.04 crores. Year-over-year, the total income grew by 21.9% from ₹1442.55 crores in Q3FY25. This indicates a strong upward movement in revenue generation over both the quarter and year. The upward trend in total income highlights the company's growth trajectory in its revenue streams over the analyzed periods.
Profitability
For the quarter ending Q3FY26, Gland Pharma Ltd achieved a profit before tax of ₹362.13 crores, marking a substantial quarter-over-quarter increase of 27.5% from Q2FY26, where the profit before tax was ₹283.92 crores. Year-over-year, this figure also rose by 21.0% from ₹299.30 crores in Q3FY25. The profit after tax for Q3FY26 stood at ₹261.48 crores, with a noteworthy quarter-over-quarter growth of 42.4% from ₹183.68 crores in Q2FY26 and a year-over-year rise of 27.7% from ₹204.69 crores in Q3FY25. This reflects a robust profitability performance across the quarters and the year. The earnings per share for Q3FY26 was ₹15.87, which is a 42.3% increase over the previous quarter and a 27.8% increase over the same quarter last year.
Operating Metrics
The total expenses for Gland Pharma Ltd in Q3FY26 amounted to ₹1372.06 crores, which is a 6.6% increase from Q2FY26's total expenses of ₹1287.12 crores and a 20.0% rise from ₹1143.24 crores in Q3FY25. The tax expenses for Q3FY26 were ₹100.65 crores, showing a slight quarter-over-quarter increase of 0.4% from ₹100.23 crores and a 6.4% year-over-year increase from ₹94.61 crores in Q3FY25. The data indicates an increase in operating expenses alongside revenue growth, maintaining a consistent profitability margin. The company's focus on cost management and operational efficiencies can be inferred from the stable rise in expenses relative to income growth.